Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Expected to Post Q1 2025 Earnings of ($0.27) Per Share

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Atara Biotherapeutics in a research note issued on Wednesday, May 22nd. HC Wainwright analyst R. Burns expects that the biotechnology company will post earnings of ($0.27) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Atara Biotherapeutics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.26) EPS and Q4 2025 earnings at ($0.25) EPS.

Separately, StockNews.com upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, April 5th.

Atara Biotherapeutics Stock Performance

ATRA opened at $0.70 on Thursday. The business’s 50-day simple moving average is $0.68 and its 200-day simple moving average is $0.67. Atara Biotherapeutics has a one year low of $0.20 and a one year high of $2.54. The stock has a market capitalization of $84.27 million, a P/E ratio of -0.33 and a beta of 0.70.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.14. Atara Biotherapeutics had a negative return on equity of 783.31% and a negative net margin of 671.70%. The company had revenue of $27.36 million during the quarter, compared to the consensus estimate of $27.00 million.

Insider Activity at Atara Biotherapeutics

In related news, EVP Anhco Nguyen sold 42,899 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $0.62, for a total value of $26,597.38. Following the transaction, the executive vice president now owns 898,498 shares in the company, valued at approximately $557,068.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Anhco Nguyen sold 42,899 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $0.62, for a total transaction of $26,597.38. Following the completion of the transaction, the executive vice president now directly owns 898,498 shares of the company’s stock, valued at approximately $557,068.76. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Pascal Touchon sold 81,506 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $0.62, for a total value of $50,533.72. Following the transaction, the chief executive officer now directly owns 1,829,146 shares of the company’s stock, valued at $1,134,070.52. The disclosure for this sale can be found here. Insiders have sold 188,643 shares of company stock worth $120,518 in the last quarter. Company insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Delap Wealth Advisory LLC acquired a new stake in Atara Biotherapeutics during the 1st quarter valued at $29,000. Vontobel Holding Ltd. acquired a new stake in Atara Biotherapeutics during the 4th quarter valued at $41,000. Harbor Capital Advisors Inc. grew its holdings in Atara Biotherapeutics by 368.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 208,827 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 164,206 shares during the last quarter. Private Advisor Group LLC grew its holdings in Atara Biotherapeutics by 53.0% during the 3rd quarter. Private Advisor Group LLC now owns 95,463 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 33,063 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 86,842 shares during the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.